A Phase II Study of Mocetinostat plus Gemcitabine in Patients with Persistent or Recurrent Leiomyosarcoma

Full Title

A Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse Following Prior Treatment with Gemcitabine-Containing Therapy

Purpose

Gemcitabine is a chemotherapy drug used to treat leiomyosarcoma, but sometimes the cancer continues to grow or comes back. The purpose of this study is to assess the safety and effectiveness of giving the investigational drug mocetinostat with gemcitabine in patients with leiomyosarcoma that has continued to grow or came back after prior gemcitabine therapy.

Mocetinostat works by inhibiting an enzyme involved in cancer growth called histone deacetylase (HDAC). It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have leiomyosarcoma that continued to grow or came back after prior gemcitabine therapy.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mark A. Dickson at 646-888-4164.

Protocol

15-133

Phase

II

Investigator

Co-Investigators

Diseases

Locations